Precision radiation may tame rising PSA after prostate surgery

NCT ID NCT04915508

First seen Jul 17, 2026 ยท Last updated Jul 17, 2026

Summary

This phase II trial tests a highly precise, short-course radiation therapy (SBRT) combined with hormone therapy for men whose PSA levels rise after prostate cancer surgery. The goal is to control the cancer while reducing side effects by delivering higher radiation doses in fewer sessions. The study measures quality of life and symptom changes in participants.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Stereotactic Body Radiation Therapy (SBRT) and hormone therapy
What this could lead to
If successful, this approach could offer a shorter, more precise radiation course with fewer side effects for men with rising PSA after prostatectomy.
What could go wrong
This is a mid-stage trial, so the approach may not prove effective or safe for all patients. Side effects from radiation and hormone therapy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.